Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Mirum Pharmaceuticals (MIRM) and Corbus Pharmaceuticals (CRBP)
at www.tipranks.com (Tue, 2-Jun 7:20 AM)
Xenon's Azetukalner Achieves Breakthrough Seizure Control in Phase 3 X-TOLE2 Study—Nearly 40% Achieve Year-Long Freedom After Four Years
Market Chameleon (Mon, 20-Apr 9:39 AM)
Xenon Pharmaceuticals’ $650 Million Upsized Offering Signals Confidence in Pipeline and Growth Strategy
Market Chameleon (Wed, 11-Mar 7:09 AM)
Xenon Sets March 9 for Phase 3 Epilepsy Drug Results: What the Upcoming X-TOLE2 Reveal Means for Investors
Market Chameleon (Mon, 9-Mar 9:52 AM)
Xenon's Azetukalner Achieves Landmark Results in Phase 3 X-TOLE2 Study—Poised to Redefine Epilepsy Care
Market Chameleon (Mon, 9-Mar 7:57 AM)
